Cargando…
Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance
The interferon (IFN)-mediated activation of the Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling is crucial for cell sensitivity to ionizing radiation. Several preclinical studies have reported that the IFN/STAT1 pathway mediates radioresistance in the tumor mi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321691/ https://www.ncbi.nlm.nih.gov/pubmed/32606809 http://dx.doi.org/10.2147/OTT.S256708 |
_version_ | 1783551526795476992 |
---|---|
author | Liu, Shuya Imani, Saber Deng, Youcai Pathak, Janak L Wen, Qinglian Chen, Yue Wu, Jingbo |
author_facet | Liu, Shuya Imani, Saber Deng, Youcai Pathak, Janak L Wen, Qinglian Chen, Yue Wu, Jingbo |
author_sort | Liu, Shuya |
collection | PubMed |
description | The interferon (IFN)-mediated activation of the Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling is crucial for cell sensitivity to ionizing radiation. Several preclinical studies have reported that the IFN/STAT1 pathway mediates radioresistance in the tumor microenvironment by shielding the immune responses and activating survival signaling pathways. This review focuses on the oncogenic function of the IFN/STAT1 pathway, emphasizing the major signaling pathway in radiation sensitization. Furthermore, it highlights the possibility of mediatory roles of the IFN/STAT1 pathway as a prognostic therapeutic target in the modulation of resistance to radiotherapy and chemotherapy. MicroRNA involved in the regulation of the IFN/STAT1 pathway is also discussed. A better understanding of radiation-induced IFN/STAT1 signaling will open new opportunities for the development of novel therapeutic strategies, as well as define new approaches to enhance radio-immunotherapy efficacy in the treatment of various types of cancers. |
format | Online Article Text |
id | pubmed-7321691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73216912020-06-29 Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance Liu, Shuya Imani, Saber Deng, Youcai Pathak, Janak L Wen, Qinglian Chen, Yue Wu, Jingbo Onco Targets Ther Review The interferon (IFN)-mediated activation of the Janus kinase (JAK)-signal transducer and activator of transcription 1 (STAT1) signaling is crucial for cell sensitivity to ionizing radiation. Several preclinical studies have reported that the IFN/STAT1 pathway mediates radioresistance in the tumor microenvironment by shielding the immune responses and activating survival signaling pathways. This review focuses on the oncogenic function of the IFN/STAT1 pathway, emphasizing the major signaling pathway in radiation sensitization. Furthermore, it highlights the possibility of mediatory roles of the IFN/STAT1 pathway as a prognostic therapeutic target in the modulation of resistance to radiotherapy and chemotherapy. MicroRNA involved in the regulation of the IFN/STAT1 pathway is also discussed. A better understanding of radiation-induced IFN/STAT1 signaling will open new opportunities for the development of novel therapeutic strategies, as well as define new approaches to enhance radio-immunotherapy efficacy in the treatment of various types of cancers. Dove 2020-06-24 /pmc/articles/PMC7321691/ /pubmed/32606809 http://dx.doi.org/10.2147/OTT.S256708 Text en © 2020 Liu et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Liu, Shuya Imani, Saber Deng, Youcai Pathak, Janak L Wen, Qinglian Chen, Yue Wu, Jingbo Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance |
title | Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance |
title_full | Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance |
title_fullStr | Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance |
title_full_unstemmed | Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance |
title_short | Targeting IFN/STAT1 Pathway as a Promising Strategy to Overcome Radioresistance |
title_sort | targeting ifn/stat1 pathway as a promising strategy to overcome radioresistance |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7321691/ https://www.ncbi.nlm.nih.gov/pubmed/32606809 http://dx.doi.org/10.2147/OTT.S256708 |
work_keys_str_mv | AT liushuya targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance AT imanisaber targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance AT dengyoucai targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance AT pathakjanakl targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance AT wenqinglian targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance AT chenyue targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance AT wujingbo targetingifnstat1pathwayasapromisingstrategytoovercomeradioresistance |